While high ranking suggests high chance of success if indications are chosen without pre-selecting patients within the cancer type, a low ranking of the cancer type does not suggest all patients of that cancer type should be ineligible for clinical trials of new anti-CTLA-4 antibodies. Here, CTLA4 is linked to cancer.